COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries
| العنوان: | COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries |
|---|---|
| المؤلفون: | Christian G. Reich, Osaid Alser, Kristin Kostka, Mengchun Gong, Clair Blacketer, Fredrik Nyberg, Sergio Fernandez Bertolin, Anthony G. Sena, Vignesh Subbian, Evan P. Minty, Marc A. Suchard, Thomas Falconer, David Vizcaya, Peter R. Rijnbeek, Anna Ostropolets, Carlos Areia, Albert Prats-Uribe, Lana Yin Hui Lai, Daniel R. Morales, Karthik Natarajan, Lin Zhang, Jennifer C E Lane, George Hripcsak, Martina Recalde, Michael E. Matheny, Jose D. Posada, Kristine E. Lynch, Seng Chan You, Aaron Abend, Karishma Shah, Waheed-Ul-Rahman Ahmed, Heba Alghoul, Jitendra Jonnagaddala, Eng Hooi Tan, Asieh Golozar, Yue Yang, Scott L. DuVall, Talita Duarte-Salles, Paula Casajust, Daniel Prieto-Alhambra, Dalia Dawoud, Matthew E. Spotnitz, Nigam H. Shah, Thamir M. Alshammari, Arani Vivekanantham, Patrick B. Ryan |
| المساهمون: | SmartPort@Erasmus, Medical Informatics |
| المصدر: | Rheumatology (Oxford, England), 60(SI), SI37-SI50. Oxford University Press Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Rheumatology (Oxford, England) Rheumatology (Oxford, England), vol 60, iss SI Rheumatology |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Heart disease, Cardiovascular, outcomes, open science, Hospitalisation, Pharmacology (medical), Lung, AcademicSubjects/MED00360, cohort, Health Services, Observational Health Data Sciences and Informatics, autoimmune condition, Infectious Diseases, Pneumonia & Influenza, Public Health and Health Services, Original Article, Observational Medical Outcomes Partnership, Open science, hospitalization, Cohort study, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Clinical Sciences, Immunology, Autoimmune Disease, Rheumatology, Clinical Research, Internal medicine, medicine, In patient, Autoimmune condition, Mortality, Veterans Affairs, Observational Health Data Sciences and Informatics (OHDSI), SARS-CoV-2, business.industry, hospitalisation, Prevention, COVID-19, autoimmune, medicine.disease, Comorbidity, mortality, Influenza, Arthritis & Rheumatology, Observational Medical Outcomes Partnership (OMOP), Pneumonia, Emerging Infectious Diseases, business, Kidney disease |
| الوصف: | Patients with autoimmune diseases were advised to shield to avoid COVID-19, but information on their prognosis is lacking. We characterised 30-day outcomes and mortality after hospitalisation with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza.Multinational network cohort study.Electronic health records data from Columbia University Irving Medical Center (CUIMC) (NYC, United States [US]), Optum [US], Department of Veterans Affairs (VA) (US), Information System for Research in Primary Care-Hospitalisation Linked Data (SIDIAP-H) (Spain), and claims data from IQVIA Open Claims (US) and Health Insurance and Review Assessment (HIRA) (South Korea).All patients with prevalent autoimmune diseases, diagnosed and/or hospitalised between January and June 2020 with COVID-19, and similar patients hospitalised with influenza in 2017-2018 were included.30-day complications during hospitalisation and death.We studied 133,589 patients diagnosed and 48,418 hospitalised with COVID-19 with prevalent autoimmune diseases. The majority of participants were female (60.5% to 65.9%) and aged ≥50 years. The most prevalent autoimmune conditions were psoriasis (3.5 to 32.5%), rheumatoid arthritis (3.9 to 18.9%), and vasculitis (3.3 to 17.6%). Amongst hospitalised patients, Type 1 diabetes was the most common autoimmune condition (4.8% to 7.5%) in US databases, rheumatoid arthritis in HIRA (18.9%), and psoriasis in SIDIAP-H (26.4%).Compared to 70,660 hospitalised with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2% to 4.3% versus 6.3% to 24.6%).Patients with autoimmune diseases had high rates of respiratory complications and 30-day mortality following a hospitalization with COVID-19. Compared to influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality. Future studies should investigate predictors of poor outcomes in COVID-19 patients with autoimmune diseases.Patients with autoimmune conditions may be at increased risk of COVID-19 infection andcomplications.There is a paucity of evidence characterising the outcomes of hospitalised COVID-19 patients with prevalent autoimmune conditions.Most people with autoimmune diseases who required hospitalisation for COVID-19 were women, aged 50 years or older, and had substantial previous comorbidities.Patients who were hospitalised with COVID-19 and had prevalent autoimmune diseases had higher prevalence of hypertension, chronic kidney disease, heart disease, and Type 2 diabetes as compared to those with prevalent autoimmune diseases who were diagnosed with COVID-19.A variable proportion of 6% to 25% across data sources died within one month of hospitalisation with COVID-19 and prevalent autoimmune diseases.For people with autoimmune diseases, COVID-19 hospitalisation was associated with worse outcomes and 30-day mortality compared to admission with influenza in the 2017-2018 season. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1462-0324 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0217f6b8f40e529fb1f8c0f95e8530a3 https://pure.eur.nl/en/publications/17e09549-5a55-449a-8ece-02dd03da9530 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....0217f6b8f40e529fb1f8c0f95e8530a3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14620324 |
|---|